Hematology
Yang J, Eickbush TH. RNA-induced changes in the activity of the endonuclease encoded by the R2 retrotransposable element. Mol Cell Biol. 1998 Jun;18(6):3455-65.
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Anthony MS, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. Presented at the Symposium on Phytoestrogen Research Methods; September 1997. Tucson, AZ.
Abstract not available at this time.
Anthony M, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. J. Med. Food. 1999;2(3-4):263-6.
Abstract not available at this time.
Karakosta P, Chatzi L, Plana E, Margioris A, Castanas E, Kogevinas M. Leptin levels in cord blood and anthropometric measures at birth: a systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2011 Mar;25(2):150-63.
Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or total knee replacement. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
OBJECTIVES: The objectives of this systematic review were to identify published economic analyses of new oral anticoagulants (NOACs) for primary venous thromboembolism (VTE) prophylaxis following total hip replacement (THR) and total knee replacement (TKR) surgeries and to summarise the modelling techniques used and cost-effectiveness results.
Goyal RK, Davis KL, Cote I, Mounedji N, Kaye JA. Health care resource use and costs among polycythemia vera patients in the United States: results from an observational cohort study. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
OBJECTIVES: Thromboembolic (TE) events are a major complication of polycythemia vera (PV). Little is known about economic implications of TE events in such patients. This study aims to assess the incremental health care resource use (HCRU) and costs associated with PV and post-PV TE events in a real-world patient population.
METHODS: We conducted a retrospective cohort study of PV patients aged <65 years enrolled in employer-sponsored commercial health plans in the US.
Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x
This study aims to report resource utilisation and annual cost for chronic immune thrombocytopenia (ITP) patients enrolled consecutively and followed for 1 year. A single-centre, single-arm, retrospective 1-year observational cohort study of adult patients with chronic ITP from a French hospital was conducted. Healthcare resource utilisation and mean cost per patient (with 95% confidence intervals) were estimated for the whole group. Patients requiring at least one hospitalisation formed subgroup 1.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
There is no abstract available at this time.